- Product Sales rose 9% to $55.6 billion in 2025, led by Oncology growth of 17% to $23.7 billion and Rare Disease growth of 5% to $9.1 billion. Key growth products included Imfinzi (+29% to $6.1 billion), Tagrisso (+10% to $7.3 billion), Ultomiris (+20% to $4.7 billion), Truqap (+69% to $728 million) and Wainua ($212 million versus $85 million); Brilinta declined 38% to $823 million following generic entry, while Soliris declined 29% to $1.8 billion amid conversion to Ultomiris, biosimilar and other competition.
- AstraZeneca completed the acquisition of FibroGen China on 29 August 2025, obtaining all China rights and manufacturing for roxadustat, for total consideration of $221 million. It also obtained the remaining 50% of global Koselugo rights through an amended collaboration with MSD and acquired the ENaBL platform from EsoBiotec; the latter was accounted for as an asset acquisition. The company continued advancing a broad pipeline, including late-stage programmes for camizestrant, baxdrostat, tozorakimab, efzimfotase alfa and other oncology, CVRM, respiratory and rare-disease candidates.
- The post-Alexion Acquisition Group Review restructuring continued: 2025 restructuring costs were $237 million, including $232 million under the programme, bringing cumulative PAAGR charges to $3.414 billion. Work included severance and integration activities across HR, Finance, IT and R&D, transformation of clinical and regulatory data systems, and the Axial enterprise-resource-planning upgrade, which is planned to be substantially complete by the end of 2030. Following the decision to cease promotional activities for Andexxa, AstraZeneca reversed $138 million of inventory and related product provisions.
- Strategic collaborations remained material to operations: alliance revenue increased to $3.067 billion, including $1.798 billion from Enhertu with Daiichi Sankyo, $673 million from Tezspire with Amgen, $422 million from Beyfortus with Sanofi and $77 million from Datroway. The Enhertu and Datroway collaborations continue to operate on a global 50:50 pre-tax net-income sharing basis, except for Daiichi Sankyo's exclusive rights in Japan.
|
